Archives

  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08

    • A23187 br WORLD NEUROSURGERY e e

    2020-08-12


    WORLD NEUROSURGERY -: e1-e10, - 2019 www.journals.elsevier.com/world-neurosurgery e5
    e6 www.SCIENCEDIRECT.com
    Table 3. Cox Proportional Hazards Regression of Factors Prognostic for Brain Relapse, Systemic Relapse, and All-Cause Mortality
    All-Cause Mortality (Model
    All-Cause Mortality (Model 2: Systemic Therapy Given
    1: Systemic Therapy Given at Before Systemic and Brain
    Brain Relapse Systemic Relapse Any Time Before Death) Relapse, If Either Occurred)
    Overall Model Is
    Overall Model Is Overall Model Is Not Overall Model Is
    Statistically Significant
    Statistically Significant Statistically Significant Statistically Significant
    Factor
    Hazard Ratio P Value Hazard Ratio P Value
    Hazard Ratio P Value
    Hazard Ratio P Value
    Karnofsky Performance Status 1.01 0.46
    Cancer type
    Breast carcinoma Reference Reference Reference Reference Reference Reference Reference Reference
    Nonesmall-cell lung cancer (adenocarcinoma) 0.32 0.13
    Nonesmall-cell lung cancer (squamous cell) 0.06 0.02
    Presence of controlled extracranial metastases 0.75 0.59
    Average A23187     metastasis volume 1.00 0.93
    Systemic therapy before stereotactic radiosurgery 2.81 0.19
    Systemic therapy after stereotactic radiosurgery 0.22 <0.01
    Time between primary tumor diagnosis and brain 0.9997 0.01
    metastasis diagnosis
    OUTCOMESPATIENTONTHERAPYSYSTEMICSRS-POSTOFEFFECT RTICLEARIGINALO
    www.journals.elsevier.com/world-neurosurgery e7 
    Table 4. Cox Proportional Hazards Regression Model Assessing the Effect of BloodeBrain Barrier Permeability on Brain Relapse, Systemic Relapse, and All-Cause Mortality
    All-Cause Mortality (Model 2:
    Systemic Therapy Given Before
    Systemic and Brain Relapse, If
    Brain Relapse
    Systemic Relapse
    Either Occurred)
    Overall Model Is Statistically
    Overall Model Is Statistically
    Overall Model Is Statistically
    Significant (Likelihood Ratio Test,
    Significant (Likelihood Ratio Test,
    Significant (Likelihood Ratio Test,
    Factor
    Hazard Ratio P Value
    Hazard Ratio P Value
    Hazard Ratio P Value
    Cancer type
    Breast carcinoma
    Reference Reference
    Reference Reference
    Reference Reference
    metastasis diagnosis
    Did not receive post-SRS systemic therapy
    Reference Reference
    Reference Reference
    Reference Reference
    not cross bloodebrain barrier
    crosses bloodebrain barrier
    SRS, stereotactic radiosurgery.  TIMOUR AL-KHINDI ET AL.
    OUTCOMESPATIENTONTHERAPYSYSTEMICSRS-POSTOFEFFECT RTICLEARIGINALO
    e8 www.SCIENCEDIRECT.com
    WORLD NEUROSURGERY, https://doi.org/10.1016/j.wneu.2019.05.218  Table 5. Cox Proportional Hazards Regression Model Assessing the Effect of Systemic Therapy Type on Brain Relapse, Systemic Relapse, and All-Cause Mortality
    All-Cause Mortality (Model 2:
    Systemic Therapy Given Before
    Systemic and Brain Relapse, If Either
    Brain Relapse Systemic Relapse
    Occurred)
    Overall Model Is Not Statistically
    Overall Model Is Statistically Overall Model Is Statistically
    Significant (Likelihood Ratio Test,
    Significant (Likelihood Ratio Significant (Likelihood Ratio Test,
    Factor
    Hazard Ratio P Value
    Hazard Ratio P Value Hazard Ratio P Value
    Karnofsky Performance Status 1.01 0.77
    Cancer type
    Breast carcinoma Reference Reference Reference Reference Reference Reference
    Nonesmall-cell lung cancer (adenocarcinoma) 0.54 0.42
    Nonesmall-cell lung cancer (squamous cell) 0.14 0.12
    Presence of controlled extracranial metastases 0.96 0.95
    Average brain metastasis volume 1.00 0.95
    Systemic therapy before stereotactic radiosurgery 1.95 0.42
    Time between primary tumor diagnosis and brain 0.9998 0.03
    metastasis diagnosis
    Did not receive postestereotactic radiosurgery Reference Reference Reference Reference Reference Reference
    systemic therapy
    Systemic therapy type
    DNA damaging agent or DNA synthesis inhibitor 0.34 0.34
    Hormone receptor antagonist 1.05 0.95
    Microtubule antagonist 0.70 0.80
    Angiogenesis inhibitor Cannot assess Cannot assess <0.01 0.99
    Cannot assess Cannot assess
    TIMOUR AL-KHINDI ET AL.
    OUTCOMESPATIENTONTHERAPYSYSTEMICSRS-POSTOFEFFECT RTICLEARIGINALO
    ORIGINAL ARTICLE
    TIMOUR AL-KHINDI ET AL. EFFECT OF POST-SRS SYSTEMIC THERAPY ON PATIENT OUTCOMES